The promise of TRK inhibitors in pediatric cancers with NTRK fusions
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The promise of TRK inhibitors in pediatric cancers with NTRK fusions
Authors
Keywords
TRK fusion, NTRK fusion, Infantile fibrosarcoma, Larotrectinib, Entrectinib
Journal
Cancer Genetics
Volume 262-263, Issue -, Pages 71-79
Publisher
Elsevier BV
Online
2022-01-23
DOI
10.1016/j.cancergen.2022.01.004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Kinase drug discovery 20 years after imatinib: progress and future directions
- (2021) Philip Cohen et al. NATURE REVIEWS DRUG DISCOVERY
- Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system tumors.
- (2021) Sébastien Perreault et al. JOURNAL OF CLINICAL ONCOLOGY
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- (2020) David S Hong et al. LANCET ONCOLOGY
- Activity and safety of larotrectinib in adult patients with TRK fusion cancer: An expanded data set.
- (2020) Alexander E. Drilon et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
- (2020) Tingting Jiang et al. Acta Pharmaceutica Sinica B
- Comment on: “Tumour-agnostic drugs in paediatric cancers”, Chisholm et al., BJC 2020
- (2020) Thomas Richard William Oliver et al. BRITISH JOURNAL OF CANCER
- HGG-01. ENTRECTINIB IN RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS: UPDATED DATA IN CHILDREN AND ADOLESCENTS
- (2020) Giles Robinson et al. NEURO-ONCOLOGY
- Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
- (2019) Giles W. Robinson et al. JOURNAL OF CLINICAL ONCOLOGY
- Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.
- (2019) Cornelis Martinus van Tilburg et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance to TRK inhibition mediated by convergent MAPK pathway activation
- (2019) Emiliano Cocco et al. NATURE MEDICINE
- Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
- (2018) Theodore W Laetsch et al. LANCET ONCOLOGY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Use of Neoadjuvant Larotrectinib in the Management of Children With Locally Advanced TRK Fusion Sarcomas
- (2018) Steven G. DuBois et al. CANCER
- Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application
- (2018) Wei Yan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
- (2018) Alexander Drilon et al. Cancer Discovery
- NTRK fusion-positive cancers and TRK inhibitor therapy
- (2018) Emiliano Cocco et al. Nature Reviews Clinical Oncology
- Recurrent EML4–NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy
- (2017) Alanna J Church et al. MODERN PATHOLOGY
- Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions
- (2017) Pierre Vanden Borre et al. ONCOLOGIST
- Infantile NTRK-associated Mesenchymal Tumors
- (2017) Jessica L Davis et al. PEDIATRIC AND DEVELOPMENTAL PATHOLOGY
- Identification of NTRK fusions in pediatric mesenchymal tumors
- (2017) Dean Pavlick et al. PEDIATRIC BLOOD & CANCER
- Congenital mesoblastic nephroma 50 years after its recognition: A narrative review
- (2017) S. L. Gooskens et al. PEDIATRIC BLOOD & CANCER
- ETV6 -NTRK3 in congenital mesoblastic nephroma: A report of the SIOP/GPOH nephroblastoma study
- (2017) Christian Vokuhl et al. PEDIATRIC BLOOD & CANCER
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- (2017) Alexander Drilon et al. Cancer Discovery
- A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors
- (2017) Alexander Drilon et al. Cancer Discovery
- What hides behind the MASC: clinical response and acquired resistance to entrectinib afterETV6-NTRK3identification in a mammary analogue secretory carcinoma (MASC)
- (2016) A. Drilon et al. ANNALS OF ONCOLOGY
- NTRKfusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States
- (2016) Manju L. Prasad et al. CANCER
- Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience
- (2016) Daniel Orbach et al. EUROPEAN JOURNAL OF CANCER
- Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
- (2016) Maria Menichincheri et al. JOURNAL OF MEDICINAL CHEMISTRY
- Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
- (2016) E. Ardini et al. MOLECULAR CANCER THERAPEUTICS
- Molecular Characterization of Sporadic Pediatric Thyroid Carcinoma with the DNA/RNA ThyroSeq v2 Next-Generation Sequencing Assay
- (2016) Jennifer L. Picarsic et al. PEDIATRIC AND DEVELOPMENTAL PATHOLOGY
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
- FDA-approved small-molecule kinase inhibitors
- (2015) Peng Wu et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
- (2015) M. Russo et al. Cancer Discovery
- An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
- (2015) R. C. Doebele et al. Cancer Discovery
- Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases
- (2014) Sandra W Cowan-Jacob et al. Future Medicinal Chemistry
- The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma
- (2014) Gang Wu et al. NATURE GENETICS
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Kinase fusions are frequent in Spitz tumours and spitzoid melanomas
- (2014) Thomas Wiesner et al. Nature Communications
- TRKing Down an Old Oncogene in a New Era of Targeted Therapy
- (2014) Aria Vaishnavi et al. Cancer Discovery
- Mammary analogue secretory carcinoma: Update on a new diagnosis of salivary gland malignancy
- (2013) Roshan Sethi et al. LARYNGOSCOPE
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
- (2013) Aria Vaishnavi et al. NATURE MEDICINE
- Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1
- (2013) Mark M. Awad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secretory carcinoma of the breast: Results from the survival, epidemiology and end results database
- (2012) David P. Horowitz et al. BREAST
- Management of Unusual Histological Types of Breast Cancer
- (2012) K. A. Cadoo et al. ONCOLOGIST
- Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group
- (2011) K. J. Cohen et al. NEURO-ONCOLOGY
- Oncogenic Alterations in Papillary Thyroid Cancers of Young Patients
- (2011) Geneviève Sassolas et al. THYROID
- Mammary Analogue Secretory Carcinoma of Salivary Glands, Containing the ETV6-NTRK3 Fusion Gene: A Hitherto Undescribed Salivary Gland Tumor Entity
- (2010) Alena Skálová et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Pediatric Low-Grade Gliomas
- (2009) Angela J. Sievert et al. JOURNAL OF CHILD NEUROLOGY
- Infantile Fibrosarcoma: Management Based on the European Experience
- (2009) Daniel Orbach et al. JOURNAL OF CLINICAL ONCOLOGY
- Cellular mesoblastic nephroma (infantile renal fibrosarcoma): institutional review of the clinical, diagnostic imaging, and pathologic features of a distinctive neoplasm of infancy
- (2009) Petek Bayindir et al. PEDIATRIC RADIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More